The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s oral heart disease drug, making Camzyos (mavacamten) the first cardiac myosin inhibitor to be permitted for use in the country.
Research Roundup: Spider Silk Stabilizes Cancer-Suppressing Protein and MoreAsthma, Autism Spectrum Disorder (ASD), Cancer Cells, Cancer Therapies, Coronavirus Disease 2019 (COVID-19), Gene Mutations, Heart Attacks, Heart Disease, High Cholesterol, Karolinska Institute, Medical Journals, Parkinson's Disease, Pediatrics, Proteins, R&D, Skin test, Structure, Testing
Maybe Spider-Man was on to something. Although spider silk and synthetic forms have been used for a wide range of applications – including bullet-proof clothing, biodegradable bottles, and bandages and surgical thread – new research suggests it may have a use for cancer therapies.
Light-to-moderate alcohol consumption is linked to a reduced risk of heart attack, stroke and death among those with heart disease, according to a study published in the journal BMC Medicine on July 26.
When it comes to matters of heart health, no amount of exercise is too much, scientists said regarding research that debunks the myth that high levels of vigorous physical activity might not always be beneficial.
Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.
Further coronavirus heart impact discovered; new clues to why women fare better than menCoronavirus, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Cytokines, Food Additives, Gender Differences, Heart Disease, Heart Muscle Cells, Heart tissue, Immune Response, Men, Physics of Fluid, R&D, T-Cells, Women
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
Pfizer Inc. filed a lawsuit seeking to require the federal government to let it help Medicare beneficiaries afford two drugs to treat a rare and sometimes fatal heart condition, and which cost $225,000 a year.
Shares of Amarin Corporation were down more than 70 percent in trading after a judge ruled that generic companies can go ahead and seek approval of generic versions of the drug manufacturer’s heart disease drug Vascepa.
Novo Nordisk’s Ozempic Wins Approval for Reducing Cardiovascular Events in Diabetes PatientsApprovals, FDA, FDA/Regulatory, Glucagon-Like Peptide-1 (GLP-1) Analogs, Heart Attacks, Heart Disease, Heart-Related Death, Major Adverse Cardiovascular Events (MACE), New Indications, Stroke, Type 2 Diabetes
Novo Nordisk’s Ozempic (semaglutide) won approval from the U.S. Food and Drug Administration to reduce the risk of major adverse cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease.
One week after announcing positive data from ORION-10, the second of three 19-month Phase III trials for inclisiran for lowering cholesterol, The Medicines Co. was acquired by Novartis.